ZEISS Ups the Ante in Ophthalmic Surgery with New Cataract System

JENA, Germany – August 27, 2026 – German medical technology giant Carl Zeiss Meditec AG has officially entered a new phase of competition in the ophthalmic surgical market. At the European Society of Cataract and Refractive Surgeons (ESCRS) congress in London, the company today unveiled a dedicated cataract-only configuration for its EVA NEXUS™ surgical system, a move poised to send ripples through the multi-billion dollar industry. The system, a key asset from its strategic 2024 acquisition of DORC, is designed to deliver a new level of precision and control to the world’s most common surgical procedure.

A Strategic Play in a Competitive Arena

This launch is far more than a standard product debut; it is a calculated maneuver in a market projected to reach nearly $40 billion by 2033. The cataract surgery device segment represents the largest piece of this lucrative pie, driven by an aging global population and the sheer volume of procedures—approximately 30 million performed annually. The introduction of a specialized system underscores a clear intent to capture significant market share.

The move masterfully leverages ZEISS's €985 million acquisition of the Dutch Ophthalmic Research Center (DORC), which brought the highly regarded EVA NEXUS platform into its portfolio. While the platform was initially celebrated for its dual capabilities in both retinal and cataract surgery, this new cataract-exclusive configuration signals a direct and focused challenge to the market’s established leaders.

Titans like Alcon, with its CENTURION® Vision System, and Johnson & Johnson Vision, with its VERITAS™ platform, have long dominated the space. These companies, along with Bausch + Lomb and its Stellaris Elite® system, have created a high barrier to entry built on years of surgeon loyalty and extensive product ecosystems. ZEISS is betting that its integrated approach—the ZEISS Cataract Workflow—combined with the specialized performance of the DORC EVA NEXUS, will provide a compelling alternative for surgeons seeking end-to-end efficiency and superior control.

Redefining Surgical Control Through Advanced Engineering

At the heart of the new system is a suite of technologies meticulously engineered to solve the most delicate challenges of phacoemulsification, the ultrasonic procedure used to break up and remove a clouded lens. The company's claims center on three core innovations: performance, stability, and control.

The VacuFlow VTi technology, powered by what the company calls "Valve Timing Intelligence," promises a pulsation-free, highly responsive fluidics system. For surgeons, this translates to a more stable anterior chamber of the eye during the procedure. This stability is a critical factor in minimizing the risk of complications like surge—a sudden pressure drop that can endanger delicate ocular structures and turn a routine procedure into a complex one.

Complementing this is the SMART IOP™ feature, which actively compensates for pressure fluctuations in real-time. According to company data, this provides up to 73% higher responsiveness compared to its predecessor, maintaining a constant, stable intraocular pressure that gives surgeons a more predictable and controlled environment. This level of automated stability allows the surgeon to focus more on the intricate maneuvers of the surgery itself.

"With the newly configured DORC EVA NEXUS cataract solution, ZEISS' advanced technology is redefining how cataract surgeons can operate in the OR - designed for streamlined performance, stability and control - supporting surgical decisions and procedural precision," stated Dr. Dominik Beck, Head of Posterior Surgery Business Sector at ZEISS Medical Technology, in the announcement.

The system also includes the compact EVA SURE TOUCH phaco handpiece and customizable pre-sets for different cataract grades, allowing surgeons to tailor the device’s parameters on the fly via footswitch or screen. This level of customization streamlines the surgical process, saving valuable time in the operating room and ensuring the energy delivered is optimized for each patient's specific condition.

From the Operating Room to Patient Outcomes

While the technical specifications are impressive for medical professionals, the ultimate measure of success for any medical innovation is its impact on patient care. The advancements in the DORC EVA NEXUS system are directly linked to the potential for improved patient safety and better visual outcomes.

A more stable and controlled surgical environment significantly reduces the potential for intraoperative complications, such as damage to the corneal endothelium or the posterior capsule that holds the new intraocular lens. By minimizing trauma to the eye, the technology can lead to less post-operative inflammation and potentially faster recovery times, allowing patients to return to their daily lives with restored vision more quickly.

Dr. Marcus Drodofsky, a cataract surgeon from Germany who has used the new platform, noted the broader impact. "DORC EVA NEXUS benefits everyone in the operating room; my staff and I feel more in control during surgery, which contributes to an improved patient experience and surgical outcomes," he shared. His experience, having relied on the DORC EVA predecessor for over a decade, lends significant weight to the claims of meaningful innovation in the latest generation.

For the millions of people who undergo cataract surgery each year, these incremental improvements in safety and efficiency are profound. The procedure is already one of the safest and most effective in all of medicine, and technologies like this continue to push the boundaries of what is possible, reinforcing patient confidence in achieving life-changing results.

Phased Rollout and Future Outlook

ZEISS is pursuing a strategic, phased rollout for the new system. It will first become available in select European markets beginning in September 2026, a common approach that allows the company to gather initial market feedback while navigating the complex web of global regulatory approvals. Securing clearances from bodies like the U.S. Food and Drug Administration (FDA) and other international agencies will be the next major hurdle for a full global launch.

The integration of the DORC EVA NEXUS into the comprehensive ZEISS Cataract Workflow is perhaps the most significant long-term play. Modern medical technology is increasingly about creating seamless digital and physical ecosystems. By connecting diagnostic equipment, surgical planning software, and the surgical system itself, ZEISS aims to offer a holistic solution that enhances precision from initial consultation to final post-operative check. This strategy not only builds customer loyalty but also creates a powerful data feedback loop for future innovation.

The debut of this dedicated cataract system demonstrates that the "early innings" of transformation in ophthalmic surgery are far from over, with intense competition driving a relentless pace of technological advancement.